Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DXZ4 associated non-coding transcript 2, distal (DANT2)
- Target
- DANT2
- Molecular classification
- Long non-coding RNA (lncRNA)
01
Overview
DANT2 (DXZ4 associated non-coding transcript 2, distal) is an X-linked long non-coding RNA transcribed from the region adjacent to the macrosatellite repeat DXZ4 at Xq23. It is implicated in regulating chromatin state, particularly heterochromatin formation, and shows developmental changes in expression. DANT2—and its related transcript DANT1—may function as architectural RNAs contributing to nuclear body formation and large-scale chromatin interactions. DANT2 can become hypermethylated and silenced in certain cancer contexts following recruitment of DNMT3B, pointing to a possible role in epigenetic regulation associated with disease
- Other names
- DXZ4 associated non-coding transcript 2DANT2DXZ4 associated noncoding transcript 2, DANT2Distal DXZ4-associated transcript 2Ensembl: ENSG00000235244NCBI Gene: 642776OMIM®: 301004
02
Mechanism of action
Drug-induced recruitment of DNMT3B DNA methyltransferase to DANT2 locus, resulting in hypermethylation, decreased OCT1 binding, and transcriptional silencing in cancer cells
03
Biological functions
Regulation of chromatin state at DXZ4 macrosatellite repeatInvolvement in developmental changes in chromatin compaction and heterochromatin formation at the X chromosomeCandidate architectural RNA involved in nuclear body formation, phase separation, and global RNA-RNA interaction hubs
04
Disease associations
Potential contribution to cancer through abnormal chromatin state and gene regulation; DNA methylation changes at DANT2 enhancer linked to gene silencing in breast cancer cell models
05
Safety considerations
No notable safety concerns, toxicity, or therapeutic challenges documented for DANT2, as it is not a therapeutic/receptor target nor are drugs directly developed against it.
06
Interacting drugs
Pterostilbene
07
Biomarkers
DANT2 enhancer/promoter methylation in cancer cell lines could act as an epigenetic biomarker in translational contexts, but its application is preclinical/research only as of now
Beyond the preview
Go deeper on DXZ4 associated non-coding transcript 2, distal (DANT2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DXZ4 associated non-coding transcript 2, distal (DANT2).